Wednesday, November 2, 2022 Daily Archives

Cell line platform reduces timelines by 33%, says Aragen

by

Aragen Life Sciences has launched its RapTr 2022 cell line development platform, which it says offers reduced timelines and delivers increased titres. Contract development manufacturing organization (CDMO) Aragen has launched its optimized RapTr 2022 cell line development (CLD) platform. BioProcess Insider spoke to the firm’s chief commercial officer, Ramesh Subramanian, at CPHI, Frankfurt who told us that RapTr stands for “rapid titers.” “We provide solutions to the customer and titres are important because the more protein you can make equals…

November 2, 2022

Instil Bio assesses manufacturing process as it pauses cell therapy trials

by

A decrease in manufacturing success rates has led Instil Bio to pause trials and assess the production processes for its tumor infiltrating lymphocyte (TIL) cell therapy candidates. Dallas, Texas-based cell therapy developer Instil’s lead candidate ITIL-168 is an autologous cell therapy product derived from a participant’s own TILs. The product is on Phase II/III trials for melanoma but after reporting a decrease in the rate of successful manufacturing of the product resulting in the inability to dose some patients in…

November 2, 2022

HPNE launches modular and customizable TFF system

by

The off-the-shelf OptiMaxx tangential flow filtration (TFF) system “brings open architecture” to downstream bioprocessing, says High Purity New England (HPNE). The Rhode Island-based single-use equipment supplier unveiled OptiMaxx last week to offer biomanufacturers a simpler and more customizable TFF system. “OptiMaxx brings open architecture, the versatility of being able to configure it for any processing needs,” Emily Peterson, BD manager of the OptiMaxx product line told this publication. “Whether it’s single-use or multi-use or using virtually any sensor or filter…

November 2, 2022